Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?
Minnesota Now with Nina Moini
Cathy Wurzer and Kelly Gordon

COVID-19 pills are on the way. Here's what you need to know.

A logo on a sign.
A Merck sign stands in front of the company's building in October 2013 in Summit, N.J. The FDA and CDC are expected to soon greenlight new antiviral pills — molnupiravir from Merck and Ridgeback Biotherapeutics and Paxlovid from Pfizer — that could minimize the impact of infection in COVID-19 patients.
Kena Betancur | Getty Images 2013

Go Deeper.

Create an account or log in to save stories.

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

Minnesota’s fourth wave of COVID-19 infections started in July and has never really abated. Infection numbers are encouraging at the moment, but hospitalizations and deaths remain near all-time highs, and the newly discovered omicron variant has entered the mix.

But there is some good news: The FDA and CDC are expected to soon greenlight new antiviral pills — molnupiravir from Merck and Ridgeback Biotherapeutics and Paxlovid from Pfizer — that could minimize the impact of infection in COVID-19 patients.

Dr. David Boulware is a professor of medicine in the Division of Infectious Diseases and International Medicine at the University of Minnesota. He joined host Cathy Wurzer to share what listeners should know about the new drugs.

Use the audio player above to listen to the full conversation.

Subscribe to the Minnesota Now podcast on Apple Podcasts, Google Podcasts, Spotify or wherever you get your podcasts.